NewsSOS
Vir Biotechnology expects to deliver top-line results from its ECLIPSE 1 clinical trial in the fourth quarter of 2026.
The company also said its current cash runway is projected to extend into the second half of 2028, according to the release.
ECLIPSE 1 trial timeline The fourth quarter of 2026 is the company's stated target for ECLIPSE 1 top-line data, the release shows.
No interim findings, enrollment figures, or additional trial detail accompanied the disclosure. The readout will fall in the final three months of 2026.
Keep reading